BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 19, 2010
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Tolerx preclinical data

In a mouse model of colon cancer, a murine analog of TRX518 plus Gemzar gemcitabine significantly reduced tumor burden (p<0.001) and prolonged survival (p<0.001) vs. Gemzar alone. Complete remission was observed in 65%...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >